Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 562,108
  • Shares Outstanding, K 163,880
  • Annual Sales, $ 110,700 K
  • Annual Income, $ -178,290 K
  • 60-Month Beta 1.13
  • Price/Sales 5.24
  • Price/Cash Flow N/A
  • Price/Book 1.79
Trade SGMO with:

Options Overview Details

View History
  • Implied Volatility 66.54% ( -6.80%)
  • Historical Volatility 74.61%
  • IV Percentile 17%
  • IV Rank 4.35%
  • IV High 273.18% on 10/27/22
  • IV Low 57.13% on 05/04/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 197
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 22,725
  • Open Int (30-Day) 25,278

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.37
  • Number of Estimates 7
  • High Estimate -0.33
  • Low Estimate -0.43
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -42.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.32 +2.56%
on 11/09/22
4.22 -19.43%
on 11/11/22
+0.01 (+0.29%)
since 11/07/22
3-Month
3.32 +2.56%
on 11/09/22
5.88 -42.18%
on 09/09/22
-2.25 (-39.82%)
since 09/07/22
52-Week
3.12 +8.97%
on 06/16/22
8.74 -61.10%
on 12/08/21
-5.07 (-59.86%)
since 12/07/21

Most Recent Stories

More News
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SGMO : 3.43 (-0.29%)
CERT : 17.56 (+0.40%)
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.

SGMO : 3.43 (-0.29%)
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday,...

SGMO : 3.43 (-0.29%)
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920,...

SGMO : 3.43 (-0.29%)
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920,...

SGMO : 3.43 (-0.29%)
Does Sangamo (SGMO) Have the Potential to Rally 122% as Wall Street Analysts Expect?

The consensus price target hints at a 122.2% upside potential for Sangamo (SGMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

SGMO : 3.43 (-0.29%)
Wall Street Analysts Predict a 106% Upside in Sangamo (SGMO): Here's What You Should Know

The consensus price target hints at a 106.2% upside potential for Sangamo (SGMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

SGMO : 3.43 (-0.29%)
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 17.14% and 26.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SGMO : 3.43 (-0.29%)
LGND : 67.71 (-0.18%)
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results.

SGMO : 3.43 (-0.29%)
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market closes on...

SGMO : 3.43 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 3.73
2nd Resistance Point 3.66
1st Resistance Point 3.54
Last Price 3.43
1st Support Level 3.35
2nd Support Level 3.28
3rd Support Level 3.16

See More

52-Week High 8.74
Fibonacci 61.8% 6.59
Fibonacci 50% 5.93
Fibonacci 38.2% 5.27
Last Price 3.43
52-Week Low 3.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar